Article
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
29 Mar 2021
Abstract excerpt
Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differentiation and maturation of the malignant clone targeting IDH is an emerging strategy to promote clinical responses...
Topics
Join the communities discussing this publication.